



Federal Retail Pharmacy Program Updates

Sitio web en Español para participantes del programa de vacunas COVID

Vaccine program updates

ACIP recommends Moderna vaccine for children ages 6-17

On Thursday, June 23rd, CDC's Advisory Committee on Immunization Practices (ACIP) expanded the recommendations for the use of Moderna COVID-19 vaccines to include children ages 6 through 17 years. They recommended Moderna's COVID-19 vaccines in a 2-dose primary series for children ages 6 through 17 years and in a 3-dose primary series for children ages 6 through 17 years who are moderately or severely immunocompromised. CDC Director Dr. Rochelle Walensky endorsed that recommendation and released a [statement](#).

Moderna's COVID-19 vaccines remain recommended for use for people 18 years of age and older as a primary series and as boosters and for children ages 6 months through 5 years as a primary series.

Moderna's COVID-19 vaccines' safety and effectiveness have been confirmed by clinical studies and by the millions of people who have already received them. As occurs for all vaccines—including all COVID-19 vaccines—safety monitoring will continue in all ages for whom Moderna vaccines are recommended and authorized.

CDC recommends everyone ages 6 months and older get vaccinated against COVID-19. Everyone 5 years and older should also get a COVID-19 booster, if eligible. To learn if and when a child or teen can get boosters to stay up to date with their COVID-19 vaccines, use [CDC's COVID-19 booster tool](#).

Below is a list of resources and upcoming informational activities related to the recommendations:

- Updated [Interim Clinical Considerations](#)
- Updated web pages for the public including:
 - [Moderna COVID-19 Vaccine Overview and Safety](#)

- [Stay Up to Date with Your COVID-19 Vaccines](#)
- [COVID-19 Vaccines for People who are Moderately or Severely Immunocompromised](#)
- [COVID-19 Vaccines for Children and Teens](#)
- [Resources to Promote the COVID-19 Vaccine for Children & Teens](#)
- [Clinical Guidance for COVID-19 Vaccination](#)

Key Information:

COVID-19 clinical materials webpages have been simplified, making materials easier to find:

- [Moderna COVID-19 Vaccine | CDC](#)
- [Pfizer-BioNTech COVID-19 Vaccines | CDC](#)
- [The link to COVID-related IIS codes](#)

Individual materials have been created/updated to reflect ACIP COVID-19 vaccination recommendations for children 6 months and older including standing orders, interim COVID-19 immunization schedule and screening checklist guidance as well as:

- Infographic on reading the vial label for
 - Moderna COVID-19 Vaccine (Updated with ages 6 through 11 years): [Moderna COVID-19 Vaccine Updated label Information • 6 Through 11 Years of Age \(cdc.gov\)](#)
 - Pfizer-BioNTech COVID-19 Vaccine (ages 6 months through 4 years): [Pfizer-BioNTech COVID-19 Vaccine Updated label Information • 6 Months Through 4 Years of Age \(cdc.gov\)](#)
- At-A-Glance summaries for:
 - [Moderna COVID-19 Vaccine At A Glance \(cdc.gov\)](#)
 - [Pfizer-BioNTech COVID-19 Vaccine At A Glance \(cdc.gov\)](#)

REMINDER: Moderna dark blue cap/purple label can be used for:

- 6 – 11 years – primary series
- >18 years – booster dose
- This vaccine is delivered with pediatric ancillary kits, which can be used on adults as well

Ordering the Moderna vaccine for children 6-11

After FDA/EUA and ACIP recommendation, the Moderna COVID-19 vaccine authorized for use in children ages 6 – 11 is now available for ordering. The product is a 5-dose vial, 100 dose minimum order quantity, and will come with an ancillary kit supporting pediatric vaccination. Deliveries are expected to begin as soon as Tuesday, June 28th.

- Please note this vaccine is labeled as ‘Adult/Booster Only’, this is addressed in the FDA EUA Factsheet as well as Moderna’s Dear HCP letter (links below).
 - Moderna Ages 6 -11 Factsheet: [Moderna HCP FS 6-11y 06172022 \(fda.gov\)](#)
 - Moderna ‘Dear HCP’ letter: [Moderna DHCP Letter 6 to 11 Dosing 06172022 \(fda.gov\)](#)
 - A printable infographic: [Administration of Moderna COVID-19 Vaccines | CDC](#)

Vaccine	Dosage (amount)/ Route
6 years through 11 years of age (blue vial cap with purple-bordered label)	0.5 mL/IM injection

NOTE:

- Vial label states booster doses only, which are authorized for persons ages 18 years and older.
- FDA has also authorized this product for primary series doses for children ages 6 years through 11 years.
- This is NOT authorized for booster doses for persons 6 months through 17 years.

NCPDP releases pending updates to emergency preparedness guidance document to address administration of pediatric multi-dose vaccines

The NCPDP Emergency Preparedness Task Group approved a guidance for the industry, related to the administration of Pediatric Multi-Dose vaccines.

FDA/EUA authorization may indicate a two-dose regime or a three-dose regime. In order to retain consistency with existing SCC’s based on dose number, the following SCC’s should be used for pediatric vaccine doses.

Initial Dose:

SCC of 2 “**Other Override**” - defined as, “Used when authorized by the payer in business cases not currently addressed by other SCC values,” to indicate the first dose of a pediatric vaccine is being administered.

Second Dose:

SCC of 6 “**Starter Dose**” - defined as, “The pharmacist is indicating the previous medication was a starter dose and a second dose of the medication is needed to continue treatment,” to indicate the second dose of a pediatric vaccine is being administered.

Third Dose:

SCC of 7 “**Medically Necessary**” - defined as, “The pharmacist is indicating the previous medication was the second dose of the medication is needed to continue treatment,” to indicate the third dose of a pediatric vaccine is being administered.

For details, refer to the draft [NCPDP EMERGENCY PREPAREDNESS GUIDANCE V1.15 document](#).

Pfizer DHCP Maroon Cap and Package Label Discrepancy

On June 17, 2022, the US Food and Drug Administration authorized emergency use of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months through 4 years of age to provide a 3- dose series. The Pfizer-BioNTech COVID-19 Vaccine for use in children 6 months through 4 years of age is supplied in multiple dose vials with maroon caps and labels with a maroon border. After dilution each multiple dose vial contains ten doses of 0.2 mL each.

Please note the following about the Pfizer-BioNTech COVID-19 Vaccine for use in children 6 months through 4 years of age that is supplied in multiple dose vials with maroon caps and labels with a maroon border:

- The vial labels may state “Age 2y to < 5y” or “Age 6m to < 5y” and carton labels may state “For age 2 years to < 5 years” or “For age 6 months to < 5 years”.
- Vials with either printed age range can be used for individuals 6 months through 4 years of age.

For complete information about the Pfizer-BioNTech COVID-19 Vaccine authorized for use in children 6 months through 4 years of age supplied in multiple dose vials with maroon caps and labels with a maroon border and the most recent Fact Sheet, please see www.cvdvaccine.com.

Preview posting of COVID-19 vaccine codes and crosswalk for currently authorized vaccines and anticipation of potential vaccine availability under Emergency Use Authorization (EUA)

Note: Codes will become effective only upon EUA issuance or BLA licensure of COVID-19 vaccine(s) by the Food and Drug Administration (FDA)

The codes and crosswalk for candidate COVID-19 vaccines will be posted for preview in phases as the late-stage clinical trials for candidate vaccines progress. Additional vaccines or codes will be added to this list as they enter late-stage clinical trials or prepare applications for FDA authorization.

The following downloadable table provides a summary of the currently authorized vaccine codes and a preview of the vaccine codes that will be activated if the FDA authorizes use and ACIP votes to recommend the candidate vaccines.

To support this effort, the CDC is working closely with data partners responsible for the creation and distribution of vaccine codes and drug compendia publishers to coordinate the release of codes in advance of potential EUAs to enable systems and users that require these codes to prepare in advance.

The codes for these vaccines are also included in the vaccine code set files unless otherwise noted in the table. Additional code details and fields values are included in the vaccine code sets.

American Medical Association (AMA) COVID-19 CPT® vaccine product and administration codes are now available on the AMA web site. The CPT vaccine product codes are included in the Preview COVID-19 table and the CDC vaccine code sets. You can access further information regarding the COVID-19 CPT codes, as well as the associated coding guidance, using the following link:

<https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes>

Download the Preview Table for US vaccine administration only: [Excel Version](#)

See more at <https://www.cdc.gov/vaccines/programs/iis/COVID-19-related-codes.html>

CDC adds scenarios for pediatric vaccination timing, spacing, and transitioning from younger to older age groups

CDC added the following considerations related to the timing, spacing, and interchangeability of COVID-19 vaccines that apply to the recommendations and schedules for people who are not moderately or severely immunocompromised and people who are moderately or severely immunocompromised.

- 4-day grace period
- Interchangeability of COVID-19 vaccine products
- Coadministration of COVID-19 vaccines with other vaccines
- Transitioning from a younger to older age group
 - Pfizer-BioNTech COVID-19 Vaccine
 - Moderna COVID-19 Vaccine
- Vaccination after SARS-CoV-2 Infection

Please see the detailed considerations [here](#).

New at-a-glance vaccine schedule graphic

Download the new vaccine schedule graphic [here](#).

V-Safe reminder

The CDC has updated V-Safe. Please remind your patients about this important resource. [Click here](#) for V-safe print resources.

Pfizer and Moderna Training Schedules

Pfizer Training: Pfizer has expanded its training sessions to address questions about currently recommended COVID-19 vaccine products as well as vaccines for children that are anticipated to be approved through an EUA. Trainings now include presentations on COVID-19 vaccines with a MAROON Cap for individuals 6 months through 4 years of age. For details, see [dates and links for upcoming training sessions](#). While current trainings follow a Tuesday, Wednesday, Thursday schedule, Daily trainings (Monday through Friday) began Monday, June 20, 2022, and will continue at least through July 8, 2022 (with no training on July 4th).

Moderna Training: Moderna is offering training webinars on COVID-19 vaccine products beginning today, June 28. [Register here](#).

CDC training materials for administering vaccine to young children

The CDC has a host of information and materials for administering vaccine to young children. These include training guidelines, e-learning, videos and printable job aids. All materials can be accessed from this page: [Vaccine Administration Resource Library](#)

Other resources:

- [Managing anaphylaxis, all ages](#)
- [General Best Practice Guidelines for Immunization](#)

July 4th holiday schedule

	Sat. 7/2	Sun. 7/3	Mon. 7/4	Tues. 7/4	Wed. 7/5
Pfizer	No deliveries	No deliveries	No deliveries	Friday orders delivered	Deliveries
McKesson Specialty	No deliveries	No deliveries	No deliveries	No deliveries	Deliveries

Share your success stories as you vaccinate your pediatric patients!

Send us your success story and pictures of pediatric vaccinations to COVIDVaccines@AmerisourceBergen.com.

Oral antivirals program updates

Antiviral therapeutics allocation requests now available via ABC Order!

Pharmacies participating in the FRPTP may now request COVID-19 Paxlovid and Molnupiravir allocation through the ABC Order COVID portal, similar to how COVID19 vaccines are requested. Email requests for therapeutics shipments will no longer be accepted. If you do not request therapeutics allocation through the ABC Order COVID portal, therapeutics inventory will not be shipped to your pharmacy. Allocation requests placed before 12pm ET Wednesdays will be delivered to your pharmacy early the following week. Orders submitted after 12pm on Wednesdays won't be processed until the next cycle.

Resources

Fact sheets

There are multiple fact sheets available for your use:

- [Moderna fact sheets](#)

- [Pfizer-BioNTech fact sheets](#)
- [COVID-19 vaccines for children and teens](#)

Pediatric Operational Planning Guide

The CDC has updated the Pediatric Operational Planning Guide. The updated guide has been posted here: [COVID-19 Vaccination for Children | CDC](#). The direct link to the PDF of the guide is here: [Pediatric-Planning-Guide.pdf \(cdc.gov\)](#). See additional information about pre-ordering these vaccines in the article above.

New to the oral antivirals program? Download these resources!

- [Implementation Guide](#)
- [FAQ](#)

COVID-19 Treatment Marketing Materials

Let your patients know that you have COVID-19 treatments available at your pharmacy with new print and digital marketing materials. Visit the “Coronavirus” library in [Brand Central Station](#) and [SOCi](#) to access the materials.



Surveys, reporting, reminders

Survey: Interest in administering EVUSHELD™

Please tell us if you are interested in administering [EVUSHELD™](#) through this [quick survey](#).

Survey: Partnering with Long-Term Care facilities

The CDC has asked if any pharmacies participating in FRPP are currently partnering with any Long-Term Care Facilities, or if they would be able to. Please take this [brief survey](#).

Are you interested in dispensing COVID-19 antiviral therapies?

If you are interested in participating in the antiviral program, please email the Elevate Enrollments team at elevateenrollments@amerisourcebergen.com.

Questions? Continue to work with your Business Coach or Sales Executive or send questions to COVIDVaccines@AmerisourceBergen.com. Please include your pharmacy name and NCPDP on all communications. This information will help us expedite our response to you.

AmerisourceBergen



This email was sent to melliott@amerisourcebergen.com because you have an account with or are a valued partner of AmerisourceBergen.

AmerisourceBergen - 1 West First Avenue Conshohocken, PA 19428

© 2022 AmerisourceBergen. All Rights Reserved.